GlobeNewswire: Novo Nordisk A/S Contains the last 10 of 3725 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T06:03:35ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/18/2847931/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html?f=22&fvtc=4&fvtv=20039Novo Nordisk A/S - share repurchase programme2024-03-18T14:18:20Z<![CDATA[Bagsværd, Denmark, 18 March 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2023.]]>https://www.globenewswire.com/news-release/2024/03/11/2843796/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html?f=22&fvtc=4&fvtv=20039Novo Nordisk A/S - share repurchase programme2024-03-11T12:46:36Z<![CDATA[Bagsværd, Denmark, 11 March 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2023.]]>https://www.globenewswire.com/news-release/2024/03/08/2843283/0/en/Wegovy-approved-in-the-US-for-cardiovascular-risk-reduction-in-people-with-overweight-or-obesity-and-established-cardiovascular-disease.html?f=22&fvtc=4&fvtv=20039Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease2024-03-08T18:42:10Z<![CDATA[Bagsværd, Denmark, 8 March 2024 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a label expansion for Wegovy® based on a supplemental New Drug Application (sNDA) for the indication of reducing risks of major adverse cardiovascular events (MACE) including cardiovascular death, non-fatal heart attack (myocardial infarction) or non-fatal stroke in adults with either overweight or obesity and established cardiovascular disease (CVD).]]>https://www.globenewswire.com/news-release/2024/03/07/2841943/0/en/Highlights-to-be-presented-at-Novo-Nordisk-s-Capital-Markets-Day-2024.html?f=22&fvtc=4&fvtv=20039Highlights to be presented at Novo Nordisk’s Capital Markets Day 20242024-03-07T07:00:42Z<![CDATA[Bagsværd, Denmark, 7 March 2024 – Novo Nordisk is today hosting a Capital Markets Day (CMD) where the company is providing a progress update on its Strategic Aspirations 2025.]]>https://www.globenewswire.com/news-release/2024/03/05/2840191/0/en/Novo-Nordisk-A-S-Semaglutide-1-0-mg-demonstrates-24-reduction-in-the-risk-of-kidney-disease-related-events-in-people-with-type-2-diabetes-and-chronic-kidney-disease-in-the-FLOW-tri.html?f=22&fvtc=4&fvtv=20039Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial2024-03-05T09:53:48Z<![CDATA[Bagsværd, Denmark, 5 March 2024 – Novo Nordisk today announced the headline results from the kidney outcomes trial FLOW. The announcement today follows the decision to stop the trial early due to efficacy, which was announced on 10 October 2023, based on a recommendation from an Independent Data Monitoring Committee. The double-blind trial compared injectable semaglutide 1.0 mg with placebo as an adjunct to standard of care for prevention of progression of kidney impairment and risk of kidney and cardiovascular mortality in people with type 2 diabetes and chronic kidney disease (CKD). The trial enrolled 3,533 people with type 2 diabetes and CKD.]]>https://www.globenewswire.com/news-release/2024/03/04/2839692/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html?f=22&fvtc=4&fvtv=20039Novo Nordisk A/S - share repurchase programme2024-03-04T14:29:10Z<![CDATA[Novo Nordisk A/S – Share repurchase programme]]>https://www.globenewswire.com/news-release/2024/02/26/2834952/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html?f=22&fvtc=4&fvtv=20039Novo Nordisk A/S - share repurchase programme2024-02-26T11:02:53Z<![CDATA[Bagsværd, Denmark, 26 February 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2023.]]>https://www.globenewswire.com/news-release/2024/02/21/2832822/0/en/Notice-for-the-Annual-General-Meeting-of-Novo-Nordisk-A-S.html?f=22&fvtc=4&fvtv=20039Notice for the Annual General Meeting of Novo Nordisk A/S2024-02-21T14:03:29Z<![CDATA[Bagsværd, Denmark, 21 February 2024 – The Annual General Meeting of Novo Nordisk A/S will be held on:]]>https://www.globenewswire.com/news-release/2024/02/19/2831299/0/en/Novo-Nordisk-A-S-Share-repurchase-programme.html?f=22&fvtc=4&fvtv=20039Novo Nordisk A/S – Share repurchase programme2024-02-19T14:29:28Z<![CDATA[Bagsværd, Denmark, 19 February 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2023.]]>https://www.globenewswire.com/news-release/2024/02/14/2828973/0/en/Novo-Nordisk-A-S-Trading-in-Novo-Nordisk-shares-by-board-members-executives-and-associated-persons.html?f=22&fvtc=4&fvtv=20039Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons2024-02-14T11:59:42Z<![CDATA[Bagsværd, Denmark, 14 February 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.]]>